The LCRF Research Grant on Overcoming Resistance in Lung Cancer is a focused funding mechanism from the Lung Cancer Research Foundation (LCRF) targeting one of the most critical unmet needs in thoracic oncology: understanding, preventing, and overcoming drug resistance across all lung cancer histologies. The programme funds mechanistic, developmental, and translational projects addressing resistance to targeted therapies, immunotherapies, chemotherapy, radiotherapy, and antibody-drug conjugates, including in rare and challenging settings such as leptomeningeal and brain metastases. Priority areas include histological transformation, oligometastatic disease, uncommon mutations, non-genomic resistance mechanisms, and novel diagnostic biomarkers to monitor treatment response and relapse. Despite being the world’s leading cause of cancer death, lung cancer research remains critically underfunded, making this one of the few dedicated resistance-focused mechanisms globally open to international applicants.
Eligibility Criteria:
Applicants must:
- Be primarily affiliated with a non-profit academic or research institution
- Be a postdoctoral researcher, clinical fellow, or early- to mid-career investigator
- Have less than 7 years of experience since their initial faculty appointment
- Not have received LCRF funding within the last 4 years
- Not apply to more than one LCRF grant track in the same cycle (as lead or co-investigator)
There are no citizenship or geographic restrictions — applicants from international institutions are eligible.
Funding Details:
- Grant amount: Up to $150,000 USD total
- Grant term: 2 years
- Covers personnel, supplies, and research-related expenses per RFA guidelines
Deadline:
- Full proposal deadline: 2 June 2026
Where to go for further information:
- Programme page
- Application portal: ProposalCentral
- Contact: grants@LCRF.org